Physician profile
Peter D Park
NPI 1689636078
$4,813.10
in general payments reported to CMS, 2019-2025
29 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $261 · 2021: $490 · 2022: $599 · 2023: $752 · 2024: $1,085 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,889 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,888.80 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,763.79 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $526.64 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $420.29 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $241.36 | 2019-2025 | |
| Qol Medical, LLC | $174.48 | 2019-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.52 | 2019-2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $145.01 | 2019-2025 | Linzess |
| Boston Scientific Corporation | $136.10 | 2024-2025 | Cre Pro, Watchman Flx |
| Janssen Scientific Affairs, LLC | $120.62 | 2019 | |
| Gilead Sciences, INC. | $115.12 | 2021-2024 | |
| Ardelyx, INC. | $110.87 | 2023-2025 | Ibsrela |
| Medtronic, INC. | $107.57 | 2021-2024 | Interstim, Pillcam |
| Intercept Pharmaceuticals, INC. | $91.50 | 2022-2025 | Ocaliva |
| Celgene Corporation | $86.61 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $85.69 | 2023-2025 | Dupixent |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $69.37 | 2025 | Vowst |
| Phathom Pharmaceuticals, INC. | $60.17 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $57.75 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $47.10 | 2021-2025 | Rebyota |
| Daiichi Sankyo INC. | $39.07 | 2021 | |
| Braintree Laboratories, INC. | $38.56 | 2020-2021 | |
| Sandoz INC. | $38.41 | 2023 | Hyrimoz |
| Merck Sharp & Dohme LLC | $30.43 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $30.00 | 2020 | |
| Genzyme Corporation | $28.10 | 2023 | |
| Alkermes, INC. | $24.91 | 2022 | |
| Lilly USA, LLC | $23.10 | 2024 | Omvoh |
| Redhill Biopharma INC. | $19.38 | 2020 | |
| Shire North American Group INC | $15.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.